Gefitinib
Structural formula | ||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
General | ||||||||||||||||||||||
Non-proprietary name | Gefitinib | |||||||||||||||||||||
other names |
N - (3-chloro-4-fluorophenyl) -7-methoxy-6- [3- (morpholin-4-yl) propoxy] quinazolin-4-amine ( IUPAC ) |
|||||||||||||||||||||
Molecular formula | C 22 H 24 ClFN 4 O 3 | |||||||||||||||||||||
Brief description |
white, crystalline, non- hygroscopic powder |
|||||||||||||||||||||
External identifiers / databases | ||||||||||||||||||||||
|
||||||||||||||||||||||
Drug information | ||||||||||||||||||||||
ATC code | ||||||||||||||||||||||
Drug class | ||||||||||||||||||||||
Mechanism of action | ||||||||||||||||||||||
properties | ||||||||||||||||||||||
Molar mass | 446.90 g · mol -1 | |||||||||||||||||||||
Physical state |
firmly |
|||||||||||||||||||||
Melting point | ||||||||||||||||||||||
solubility |
Easily soluble in glacial acetic acid and in dimethyl sulfoxide , soluble in pyridine , sparingly soluble in tetrahydrofuran and slightly soluble in methanol , ethanol , ethyl acetate , 2-propanol and acetonitrile |
|||||||||||||||||||||
safety instructions | ||||||||||||||||||||||
|
||||||||||||||||||||||
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions . |
Gefitinib ( trade name Iressa , AstraZeneca ) is a drug from the class of tyrosine kinase inhibitors to be taken as a tablet . The usual dosage is 250 mg daily.
Mechanism of action
Gefitinib mainly inhibits the tyrosine kinases from the EGFR family ( Epidermal Growth Factor Receptor ). EGF receptors are overexpressed in some tumors . Inhibition of the EGF receptors leads to a slowdown in tumor growth or even to tumor regression.
Study situation on application
In 2009 and 2010, therapeutic studies for the treatment of patients with non-small cell lung cancer were published in which the administration of Gefitinib was compared with conventional chemotherapy. In a subset of these patients, treatment with gefitinib was shown to be more effective than treatment with “standard” chemotherapy consisting of carboplatin / cisplatin and taxol . However, gefitinib was only more effective if the corresponding patients had mutations in the EGFR gene. In the absence of such mutations, gefitinib was less effective than standard therapy. These mutations were more common in female patients, patients who had never smoked, and patients with adenocarcinoma.
These results led the American Society of Clinical Oncology to recommend the use of gefitinib in patients with EGFR mutations in its 2009 guidelines for the treatment of non-small cell lung cancer.
On 24 June 2009, the issued European Commission said AstraZeneca AB, a marketing authorization of Iressa throughout the European Union for the treatment of non-small cell lung cancer with activating EGFR mutations.
Unwanted side effects
The main possible side effects of Gefitinib are rashes and diarrhea .
Individual evidence
- ^ A b c The Merck Index : An Encyclopedia of Chemicals, Drugs, and Biologicals. 14th edition. Merck & Co., Whitehouse Station, NJ, USA, 2006, ISBN 0-911910-00-X .
- ↑ a b Safety data sheet from Caymanchem , accessed on May 26, 2020.
- ↑ TS Mok, YL Wu, S. Thongprasert, CH Yang, DT Chu, N. Saijo, P. Sunpaweravong, B. Han, B. Margono, Y. Ichinose, Y. Nishiwaki, Y. Ohe, JJ Yang, B. Chewaskulyong, H. Jiang, EL Duffield, CL Watkins, AA Armor, M. Fukuoka: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. In: N Engl J Med . 361 (10), 2009, pp. 947-957. PMID 19692680 .
- ↑ T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, J. Tsurutani, T. Seto, M. Satouchi, H. Tada, T. Hirashima, K. Asami, N. Katakami, M Takada, H. Yoshioka, K. Shibata, S. Kudoh, E. Shimizu, H. Saito, S. Toyooka, K. Nakagawa, M. Fukuoka; West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harboring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. In: Lancet Oncol. 11 (2), 2010, pp. 121-128. PMID 20022809 .
- ↑ CG Azzoli, S. Baker Jr, S. Temin, W. Pao, T. Aliff, J. Brahmer, DH Johnson, JL Laskin, G. Masters, D. Milton, L. Nordquist, DG Pfister, S. Piantadosi, JH Schiller, R. Smith, TJ Smith, JR Strawn, D. Trent, G. Giaccone; American Society of Clinical Oncology: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. In: J Clin Oncol . 27 (36), 2009, pp. 6251-6266. PMID 19917871 .
- ↑ EMEA: EPAR summary for the public: Iressa - Gefitinib (PDF; 39 kB).